For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...